Download PDF
TumorDiagnostik & Therapie 2004; 25(2): 82-88
DOI: 10.1055/s-2004-813086
Thieme Onkologie aktuell

© Georg Thieme Verlag Stuttgart · New York

PSA-gesteuerte Früherkennung des Prostatakarzinoms

Panikmache oder Fortschritt?PSA Related Screening of Prostate Cancer Panic or Improvement? P. Fornara1 , A. Jurczok1
  • 1Klinik und Poliklinik für Urologie, Medizinische Fakultät, Martin-Luther-Universität Halle/Wittenberg
Further Information

Publication History

Publication Date:
21 April 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die frühe Diagnose und die radikale Therapie des Prostatakarzinoms ist die einzige Chance auf Heilung. Die PSA-gesteuerte Früherkennung führt zu einer Vorverlegung des Diagnosezeitpunktes um 5 bis 10 Jahre [1] [2] [3]. Obgleich Früherkennungsmaßnahmen eine Verschiebung der Tumorstadien beim Diagnosezeitpunkt hin zu organbegrenzten Tumoren bewirkt und dies einen therapeutischen Vorteil darstellt, wird die Etablierung von Früherkennungsmaßnahmen weiterhin kontrovers diskutiert. Diese Diskussion findet ihre Ursache in dem unbestimmten Anteil an überdiagnostizierten Patienten durch flächendeckende Früherkennungsmaßnahmen sowie dem daraus resultierenden unklaren Risiko-/Nutzen-Gleichgewicht für den Patienten. Ob die krankheitsspezifische Mortalität des Prostatakarzinoms durch Früherkennungsmaßnahmen tatsächlich verringert werden kann, können nur Ergebnisse aus randomisierten Studien klären. Diese fehlen zur Zeit noch und stehen erst im Jahre 2005 bzw. 2008 zur Verfügung. Ein Ausweg kann nur eine umfassende individuelle Aufklärung des Patienten über die Wertigkeit der zur Verfügung stehenden Früherkennungsinstrumente, die daraus evtl. resultierenden notwendigen Folgeuntersuchungen, deren Risiko sowie gegebenenfalls notwendige therapeutische Konsequenzen und deren Risiko-/Nutzen-Profil sein [4]. Über den aktuellen Stand der European Randomized Study of Screening for Prostate Cancer” informiert F. H. Schröder im British Journal of Urology International im Dezember 2003.

Abstract

The early detection of prostate cancer and the aggressive treatment is the only chance for a cure. The use of PSA-related screening techniques accelerates the diagnosis of the disease by 5 - 10 years [1] [2] [3]. While such early detection regimens shift the stage at the time of detection towards locally confined disease, and while there is no doubt that early treatment is the only way of curing prostate cancer, the application of screening in practice and healthcare policy remains controversial because there are uncertainties about the degree of „over-diagnosis” which most probably results from screening and uncertainties about the risk-benefit balance. Randomized studies will show whether early detection of prostate cancer can reduce cancer-specific mortality. Conclusive data will not be available before 2005 respectively 2008. At that time, only the validated complied information about the risks and benefits of screening and about the possible therapeutic consequences may provide a way out of this current dilemma [4]. A synopsis of the (European Randomized Study of Screening for Prostate Cancer) was given by F. H. Schröder in the British Journal of Urology International, December 2003.

Schlüsselwörter

Prostatakarzinom - Früherkennung - prostataspezifisches Antigen

Key words

Prostate cancer - screening - prostate specific antigen

Literatur

  • 1 Gann P H, Hennekens C H, Stampfer M J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.  JAMA. 1995;  273 289-294
    CrossrefPubMedGoogle Scholar
  • 2 Stenman U H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.  Lancet. 1994;  344 1594-1598
    CrossrefPubMedGoogle Scholar
  • 3 Parkes C, Wald N J, Murphy P. et al . Prospective observational study to assess value of prostate specifc antigen as screening test for prostate cancer.  Br Med J. 1995;  311 1340-1343
    PubMedGoogle Scholar
  • 4 Rübben H, Schalkhauser K, Wolff J, Luboldt H J. Deutsches Krebsgesellschaft e. V. German Cancer Society e. V. S3 guideline for PSA determination in diagnosis of prostatic carcinoma.  Onkologie. 2003 Feb;  26 (1) 88-89
    CrossrefPubMedGoogle Scholar
  • 5 Kirby R, Kirny M, Feneley M, McNicholas T, McLean A, Webb J. Screening for carcinoma of the prostate: a GP based study.  Br J Uro. 1994;  74 64-71
    PubMedGoogle Scholar
  • 6 Schmid H, Altwein J E, Faul P, Wirth M. Screening und Früherkennung des Prostatakarzinoms.  Dtsch Ärztebl. 1999;  96 12-A772 - 777
    PubMedGoogle Scholar
  • 7 Schwartz F, Robra B. Stand und Perspektiven der Forschung zur Krebsfrüherkennung. In: Schwartz F, Badura B, Brecht J, Hofmann W, Jöckel K, Trojan A (Hrsg). Public health. Berlin, Heidelberg, New York: Springer 1996
    Google Scholar
  • 8 Walsh P. The natural history of localized prostate cancer: a guide to therapy. In: Walsh P, Retik A, Stamey T, Vaughan EJ (eds.). Campbell"s Urology. 7th. ed. Philadelphia: Saunders 1997: 2539-2564
    Google Scholar
  • 9 Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, de Kernion J, Ratliff T, Kavoussi L, Dalkin B, Waters W, MacFarlane M, Southwick P. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.  J Urol. 1994;  151 1283-1290
    CrossrefPubMedGoogle Scholar
  • 10 Lubold H, Rübben J. PSA-Früherkennung des Prostatakarzinoms.  Urologe [A]. 2000;  39 22-26
    PubMedGoogle Scholar
  • 11 Oliver S E, Gunnell D, Donovan J L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA.  Lancet. 2000;  355 1788-1789
    CrossrefPubMedGoogle Scholar
  • 12 Visser O, Coebergh J WW, Schouten L J, Dijck J AAM van. Incidence of Cancer in the Netherlands 1997. Utrecht: Vereniging Van Integrale Kankercentral, 2001 7 Greenlee RT, Hill-Harmon MB, Thun M. Cancer statistics.  CA Cancer J Clin. 2001;  51 15-36
    CrossrefPubMedGoogle Scholar
  • 13 Greenlee R T, Hill-Harmon M B, Thun M. Cancer statistics.  CA Cancer J Clin. 2001;  51 15-36
    CrossrefPubMedGoogle Scholar
  • 14 Bartsch G, Horninger W, Klocker H. et al . Decrease in prostate cancer mortality following introduction of prostate specifc antigen (PSA) screening in the federal state of Tyrol, Austria.  J Urol. 2000;  163 (Suppl. 4) 88-A387
    PubMedGoogle Scholar
  • 15 Labrie F, Candas B, Dupont A. et al . Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial.  Prostate. 1999;  38 83-91
    CrossrefPubMedGoogle Scholar
  • 16 Alexander F E. Screening decreases prostate cancer death. First analysis of the 1988 Quebec prospective randomized controlled trial.  Prostate. 1999;  40 135-136
    CrossrefPubMedGoogle Scholar
  • 17 Boer R, Schröder F H. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction [letter].  Prostate. 1999;  40 130-134
    CrossrefPubMedGoogle Scholar
  • 18 Hankey B F, Feuer E J, Clegg L X. et al . Cancer Surveillance Series: Interpreting trends in prostate cancer - Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.  J Natl Cancer Inst. 1999;  91 1017-1024
    CrossrefPubMedGoogle Scholar
  • 19 Etzioni R, Legler J M, Feuer E J, Merrill R M, Cronin K A, Hankey B F. Cancer surveillance series: interpreting trends in prostate cancer - part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.  J Natl Cancer Inst. 1999;  91 1033-1039
    CrossrefPubMedGoogle Scholar
  • 20 Stanford J L, Stephenson R A, Coyle L M. et al .Prostate cancer trends, 1973 - 95. SEER Program National Cancer Institute. National Cancer Institute Monograph 1998 (http://www.seer.img.nci.nih.gov). 1998
    Google Scholar
  • 21 Etzioni R, Penson D F, Legler J M, di Tommaso D, Boer R, Gann P H, Feuer E J. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.  J Natl Cancer Inst 2002 Jul. 3;  94 (13) 981-990
    PubMedGoogle Scholar
  • 22 Walsh P C. Comment on: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.  J Natl Cancer Inst/J Urol. 2002 Jul 3/2003;  94 (13)/170 (1) 981-990; 313 - 314
    PubMedGoogle Scholar
  • 23 Madalinska J B, Essink-Bot M L, de Koning H J, Kirkels W J, Maas P J van der, Schröder F H. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.  J Clin Oncol. 2001;  19 1612-1628
    PubMedGoogle Scholar
  • 24 Litwin M S, Fitzpatrick J M, Fossa S D, Newling D WW. Defining an international research agenda for quality of life in men with prostate cancer.  Prostate. 1999;  41 58-67
    CrossrefPubMedGoogle Scholar
  • 25 Beemsterboer P M, de Koning H J, Birnie E, Maas P J van der, Schröder F H. Advanced prostate cancer. Course, care, and cost implications.  Prostate. 1999;  40 97-104
    CrossrefPubMedGoogle Scholar
  • 26 Carter H B, Pearson J D, Metter E J. et al . Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.  JAMA. 1992;  267 2215-2220
    CrossrefPubMedGoogle Scholar
  • 27 Albertsen P C, Fryback D G, Storer B E, Kolon T F, Fine J. Long-term survival among men with conservatively treated localized prostate cancer.  JAMA. 1995;  274 626-631
    CrossrefPubMedGoogle Scholar
  • 28 Albertsen P C, Hanley J A, Gleason D F, Barry M J. Competing risk analysis of men aged 55 - 74 years at diagnosis managed conservatively for clinically localized prostate cancer.  JAMA. 1998;  280 975-980
    CrossrefPubMedGoogle Scholar
  • 29 Epstein J I, Walsh P C, Carmichael M, Brendler C B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.  JAMA. 1994;  271 368-374
    CrossrefPubMedGoogle Scholar
  • 30 Schröder F H, Wildhagen M F. Rotterdam Study Group of the “European Randomised Study of Screening for Prostate Cancer” (ERSPC) . Screening for prostate cancer: evidence and perspectives.  BJU Int. 2001 Nov;  88 (8) 811-817
    CrossrefPubMedGoogle Scholar
  • 31 Catalona W J, Miller D R, Kavoussi L R. Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy.  J Urol. 1988;  140 540-543
    PubMedGoogle Scholar
  • 32 Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder F H. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region).  Prostate. 1999;  39 316-322
    CrossrefPubMedGoogle Scholar
  • 33 Hoedemaeker R F, Rietbergen J B, Kranse R, Kwast T H van der, Schröder F H. Comparison of pathologic characteristics of T1 c and non-T1 c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.  World J Urol. 1997;  15 339-345
    CrossrefPubMedGoogle Scholar
  • 34 Schröder F H, Maas P van der, Beemsterboer P. et al . Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.  J Natl Cancer Inst. 1998;  90 1817-1823
    CrossrefPubMedGoogle Scholar
  • 35 Schröder F H, Cruijsen-Koeter I van der, de Koning H J, Vis A N, Hoedemaeker R F, Kranse R. Prostate cancer detection at low prostate specific antigen.  J Urol. 2000;  163 806-812
    CrossrefPubMedGoogle Scholar
  • 36 Schröder F H, Roobol-Bouts M, Vis A N, Kwast T van der, Kranse R. Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination.  Urology. 2001;  57 83-90
    CrossrefPubMedGoogle Scholar
  • 37 Eskew L A, Bare R L, McCullough D L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate.  J Urol. 1997;  157 199-202
    PubMedGoogle Scholar
  • 38 Davidson P JT, Hop W, Kurth K H. et al . Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 - 4, N1 - 3,Mo,D1).  J Urol. 1995;  154 2118-2122
    PubMedGoogle Scholar
  • 39 Klotz L, Choo R, De Boer G. et al . PSA doubling time of prostate carcinoma managed with watchful observation alone.  J Urol. 2000;  163 (Suppl. 4) 58-A251
    PubMedGoogle Scholar
  • 40 American Urological Society .Executive Committee Report. Baltimore: American Urological Association 1992
    Google Scholar
  • 41 Weymayr C, Koch K. Mythos Krebsvorsorge, Schaden und Nutzen der Früherkennung, 1th. ed. Frankfurt a. M.: Eichborn 2003: 141-156
    Google Scholar
  • 42 Fornara P. „Stimmungsmache”. Die Deutsche Gesellschaft für Urologie ist der Auffassung, dass die Vorteile der PSA-Untersuchung die Nachteile bei weitem überwiegen.  Dtsch Ärztebl. 2003;  100 42-A-2703
    PubMedGoogle Scholar
  • 43 Schröder F H, Denis L J, Roobol M. The Story of the European Randomized Study of Screening for Prostate Cancer.  BJU Int. 2003;  92 (Suppl. 2) 1-13
    PubMedGoogle Scholar
  • 44 Auvinen A, Hugosson J. The rationale for the ERSPC trial, will it improve the knowledge base on prostate cancer screening?.  BJU Int. 2003;  92 (Suppl. 2) 14-16
    CrossrefPubMedGoogle Scholar
  • 45 Nelen V, Thys G, Neels H, Neetens I, Coebergh J W, Dourcy-Belle-Rose B, Denis L. ERSPC, features and preliminary results from the Antwerp study centre.  BJU Int. 2003;  92 (Suppl. 2) 17-21
    CrossrefPubMedGoogle Scholar
  • 46 Finne P, Stenman U H, Määttänen T, Mäkinen T, Tammela T LJ, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen P J, Lahtela J, Rissanen P, Juusela H, Hakama M, Auvinen A. The Finnish trial of prostate cancer screening, where are we now?.  BJU Int. 2003;  92 (Suppl. 2) 22-26
    CrossrefPubMedGoogle Scholar
  • 47 Villers A, Malavaud B, Rebillard X, Bataille V, Iborra F. ERSPC, features and preliminary results of France.  BJU Int. 2003;  92 (Suppl. 2) 27-29
    CrossrefPubMedGoogle Scholar
  • 48 Ciatto S, Gervasi G, Frullini P, Zendron P, Zappa M. Specific features of the Italian section of the ERSPC.  BJU Int. 2003;  92 (Suppl. 2) 30-32
    CrossrefPubMedGoogle Scholar
  • 49 Berenguer A, Luján M, Páez A, Santonja C, Pascual T. The Spanish Contribution to the European Randomized Study of Screening for Prostate Cancer.  BJU Int.. 2003;  92 (Suppl. 2) 33-38
    CrossrefPubMedGoogle Scholar
  • 50 Hugosson J, Aus G, Bergdahl S, Fernlund P, Frösing R, Lodding P, Pihl C G, Lilja H. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.  BJU Int. 2003;  92 (Suppl. 2) 39-43
    CrossrefPubMedGoogle Scholar
  • 51 Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Häfeli A, Recker F. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland.  BJU Int. 2003;  92 (Suppl. 2) 44-47
    CrossrefPubMedGoogle Scholar
  • 52 Roobol M J, Kirkels W J, Schröder F H. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).  BJU Int. 2003;  92 (Suppl. 2) 48-54
    PubMedGoogle Scholar
  • 53 Smith P H. The Data Morning Committee - Bridging the Gap Between Urology and Public Health Epidemiology.  BJU Int. 2003;  92 (Suppl. 2) 55-56
    CrossrefPubMedGoogle Scholar
  • 54 van der Kwast T H, Lopes C, Martikainen P M, Pihl C G, Santonja C, Neetens I, Di Lollo S, Hoedemaeker R F. Report of the Pathology Committe, False-positive and False-negative Diagnoses of Prostate Cancer.  BJU Int. 2003;  92 /Suppl. 2) 62-65
    CrossrefPubMedGoogle Scholar
  • 55 De Koning H J, Blom J, Merkelbach J W, Raaijmakers R, Verhaegen H, van Vliet P, Nelen V, Coebergh J WW, Hermans A, Ciatto S, Mäkinen T. Determing the cause of death in randomized screening trial(s) for prostate cancer.  BJU Int. 2003;  92 (Suppl. 2) 71-78
    CrossrefPubMedGoogle Scholar
  • 56 Ciatto S, Vis A, Finne P. How to Improve the Specificity and Sensitivity of Biopsy Technique in Screening.  BJU Int. 2003;  92 (Suppl. 2) 79-83
    CrossrefPubMedGoogle Scholar
  • 57 Páez A, Luján M, Raaijmakers R, Berenguer A. Four-year Prostate-Specific Antigen Progression in the non-Cancer Population of the European Randomized Study of Screening for Prostate Cancer.  BJU Int. 2003;  92 (Suppl. 2) 84-87
    CrossrefPubMedGoogle Scholar
  • 58 Van der Kwast T H, Roobol M J, Wildhagen M F, Martikainen P M, Määtänen L, Pihl C-G, Santonja C, Bubendorf L, Neetens I, di Lollo S, Hoedemaeker R F. Consistency of Prostate Cancer Grading Results in Screened Populations Across Europe.  BJU Int. 2003;  92 (Suppl. 2) 88-91
    CrossrefPubMedGoogle Scholar

Prof. Dr. Paolo Fornara

Klinik und Poliklinik für Urologie · Medizinische Fakultät, Martin-Luther-Universität Halle/Wittenberg

Ernst-Grube-Str. 40

06112 Halle/Saale

Phone: +49/345/5 57 14 46

Email: paolo.fornara@medizin.uni-halle.de

      >